PBM draft guidance
Executive Summary
Comment period reopened until July 31 for "Medical Product Promotion by Healthcare Organizations or Pharmacy Benefits Management Companies" draft guidance. FDA said that after reviewing the comments, it "intends to solicit public comment on a new draft guidance document"